Cargando…
Decay of Fc-dependent antibody functions after mild to moderate COVID-19
The capacity of antibodies to engage with immune cells via the Fc region is important in preventing and controlling many infectious diseases. The evolution of such antibodies during convalescence from coronavirus disease 2019 (COVID-19) is largely unknown. We develop assays to measure Fc-dependent a...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106889/ https://www.ncbi.nlm.nih.gov/pubmed/33997824 http://dx.doi.org/10.1016/j.xcrm.2021.100296 |
_version_ | 1783689851672985600 |
---|---|
author | Lee, Wen Shi Selva, Kevin John Davis, Samantha K. Wines, Bruce D. Reynaldi, Arnold Esterbauer, Robyn Kelly, Hannah G. Haycroft, Ebene R. Tan, Hyon-Xhi Juno, Jennifer A. Wheatley, Adam K. Hogarth, P. Mark Cromer, Deborah Davenport, Miles P. Chung, Amy W. Kent, Stephen J. |
author_facet | Lee, Wen Shi Selva, Kevin John Davis, Samantha K. Wines, Bruce D. Reynaldi, Arnold Esterbauer, Robyn Kelly, Hannah G. Haycroft, Ebene R. Tan, Hyon-Xhi Juno, Jennifer A. Wheatley, Adam K. Hogarth, P. Mark Cromer, Deborah Davenport, Miles P. Chung, Amy W. Kent, Stephen J. |
author_sort | Lee, Wen Shi |
collection | PubMed |
description | The capacity of antibodies to engage with immune cells via the Fc region is important in preventing and controlling many infectious diseases. The evolution of such antibodies during convalescence from coronavirus disease 2019 (COVID-19) is largely unknown. We develop assays to measure Fc-dependent antibody functions against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S)-expressing cells in serial samples from subjects primarily with mild-moderate COVID-19 up to 149 days post-infection. We find that S-specific antibodies capable of engaging Fcγ receptors decay over time, with S-specific antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent phagocytosis (ADP) activity within plasma declining accordingly. Although there is significant decay in ADCC and ADP activity, they remain readily detectable in almost all subjects at the last time point studied (94%) in contrast with neutralization activity (70%). Although it remains unclear the degree to which Fc effector functions contribute to protection against SARS-CoV-2 re-infection, our results indicate that antibodies with Fc effector functions persist longer than neutralizing antibodies. |
format | Online Article Text |
id | pubmed-8106889 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-81068892021-05-10 Decay of Fc-dependent antibody functions after mild to moderate COVID-19 Lee, Wen Shi Selva, Kevin John Davis, Samantha K. Wines, Bruce D. Reynaldi, Arnold Esterbauer, Robyn Kelly, Hannah G. Haycroft, Ebene R. Tan, Hyon-Xhi Juno, Jennifer A. Wheatley, Adam K. Hogarth, P. Mark Cromer, Deborah Davenport, Miles P. Chung, Amy W. Kent, Stephen J. Cell Rep Med Article The capacity of antibodies to engage with immune cells via the Fc region is important in preventing and controlling many infectious diseases. The evolution of such antibodies during convalescence from coronavirus disease 2019 (COVID-19) is largely unknown. We develop assays to measure Fc-dependent antibody functions against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S)-expressing cells in serial samples from subjects primarily with mild-moderate COVID-19 up to 149 days post-infection. We find that S-specific antibodies capable of engaging Fcγ receptors decay over time, with S-specific antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent phagocytosis (ADP) activity within plasma declining accordingly. Although there is significant decay in ADCC and ADP activity, they remain readily detectable in almost all subjects at the last time point studied (94%) in contrast with neutralization activity (70%). Although it remains unclear the degree to which Fc effector functions contribute to protection against SARS-CoV-2 re-infection, our results indicate that antibodies with Fc effector functions persist longer than neutralizing antibodies. Elsevier 2021-05-09 /pmc/articles/PMC8106889/ /pubmed/33997824 http://dx.doi.org/10.1016/j.xcrm.2021.100296 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Lee, Wen Shi Selva, Kevin John Davis, Samantha K. Wines, Bruce D. Reynaldi, Arnold Esterbauer, Robyn Kelly, Hannah G. Haycroft, Ebene R. Tan, Hyon-Xhi Juno, Jennifer A. Wheatley, Adam K. Hogarth, P. Mark Cromer, Deborah Davenport, Miles P. Chung, Amy W. Kent, Stephen J. Decay of Fc-dependent antibody functions after mild to moderate COVID-19 |
title | Decay of Fc-dependent antibody functions after mild to moderate COVID-19 |
title_full | Decay of Fc-dependent antibody functions after mild to moderate COVID-19 |
title_fullStr | Decay of Fc-dependent antibody functions after mild to moderate COVID-19 |
title_full_unstemmed | Decay of Fc-dependent antibody functions after mild to moderate COVID-19 |
title_short | Decay of Fc-dependent antibody functions after mild to moderate COVID-19 |
title_sort | decay of fc-dependent antibody functions after mild to moderate covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106889/ https://www.ncbi.nlm.nih.gov/pubmed/33997824 http://dx.doi.org/10.1016/j.xcrm.2021.100296 |
work_keys_str_mv | AT leewenshi decayoffcdependentantibodyfunctionsaftermildtomoderatecovid19 AT selvakevinjohn decayoffcdependentantibodyfunctionsaftermildtomoderatecovid19 AT davissamanthak decayoffcdependentantibodyfunctionsaftermildtomoderatecovid19 AT winesbruced decayoffcdependentantibodyfunctionsaftermildtomoderatecovid19 AT reynaldiarnold decayoffcdependentantibodyfunctionsaftermildtomoderatecovid19 AT esterbauerrobyn decayoffcdependentantibodyfunctionsaftermildtomoderatecovid19 AT kellyhannahg decayoffcdependentantibodyfunctionsaftermildtomoderatecovid19 AT haycroftebener decayoffcdependentantibodyfunctionsaftermildtomoderatecovid19 AT tanhyonxhi decayoffcdependentantibodyfunctionsaftermildtomoderatecovid19 AT junojennifera decayoffcdependentantibodyfunctionsaftermildtomoderatecovid19 AT wheatleyadamk decayoffcdependentantibodyfunctionsaftermildtomoderatecovid19 AT hogarthpmark decayoffcdependentantibodyfunctionsaftermildtomoderatecovid19 AT cromerdeborah decayoffcdependentantibodyfunctionsaftermildtomoderatecovid19 AT davenportmilesp decayoffcdependentantibodyfunctionsaftermildtomoderatecovid19 AT chungamyw decayoffcdependentantibodyfunctionsaftermildtomoderatecovid19 AT kentstephenj decayoffcdependentantibodyfunctionsaftermildtomoderatecovid19 |